CTN-0145: Standard versus High Dose ED-Initiated Buprenorphine Induction (NIH HEAL Initiative)

November 16, 2023 /

Kathryn Hawk, MD, MHS
Co-Principal Investigator
Yale University School of Medicine
kathryn.hawk@yale.edu

Andrew Herring, MD
Co-Principal Investigator
Highland Hospital-Alameda Health System
aherring@alamedahealthsystem.org

Gail D’Onofrio, MD, MS
Co-Principal Investigator
Yale University School of Medicine
gail.donofrio@yale.edu

This is a multisite, randomized double-blind, double-dummy, clinical trial of ED patients with moderate to severe OUD (N=320) to compare buprenorphine High Dose Induction (HDI; 24 mg) and buprenorphine Standard ED Dose Induction (SDI; 8 mg) to evaluate potential differences between HDI and SDI on the outcomes of craving, tolerability, safety, withdrawal symptoms, and illicit drug use assessed for 7 days post-randomization. The study will evaluate potential difference in rates of engagement in follow-up OUD treatment within 1-week post-randomization between the HDI and SDI participants. The study will also evaluate outcomes based on other substance use (i.e., fentanyl, stimulants, sedatives), race, housing instability and other social determinants of health.

Funded by the NIH HEAL Initiative®

Related Resources